C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland et al., Alzheimer's disease, The Lancet, vol.377, issue.9770, pp.1019-1031, 2011.
DOI : 10.1016/S0140-6736(10)61349-9

T. Golde, L. Schneider, and E. Koo, Anti-A?? Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift, Neuron, vol.69, issue.2, pp.203-213, 2011.
DOI : 10.1016/j.neuron.2011.01.002

B. Souchet, F. Guedj, I. Sahun, A. Duchon, F. Daubigney et al., Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage, Neurobiology of Disease, vol.69, pp.65-75, 2014.
DOI : 10.1016/j.nbd.2014.04.016

J. Hamelet, C. Noll, C. Ripoll, J. Paul, J. N. Delabar et al., Effect of hyperhomocysteinemia on the protein kinase DYRK1A in liver of mice, Biochemical and Biophysical Research Communications, vol.378, issue.3, pp.673-677, 2009.
DOI : 10.1016/j.bbrc.2008.11.126

R. Kimura, K. Kamino, M. Yamamoto, A. Nuripa, T. Kida et al., The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between ??-amyloid production and tau phosphorylation in Alzheimer disease, Human Molecular Genetics, vol.16, issue.1, pp.15-23, 2007.
DOI : 10.1093/hmg/ddl437

F. Guedj, C. Sebrie, I. Rivals, A. Ledru, E. Paly et al., Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A, PLoS ONE, vol.21, issue.25, p.4606, 2009.
DOI : 10.1371/journal.pone.0004606.s001

D. Toiber, G. Azkona, S. Ben-ari, N. Toran, H. Soreq et al., Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations, Neurobiology of Disease, vol.40, issue.1, pp.348-359, 2010.
DOI : 10.1016/j.nbd.2010.06.011

C. Planque, C. Ripoll, C. Guedj, F. Diez, A. Ducros et al., DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase, PLoS ONE, vol.4, p.7540, 2009.

C. Planque, J. Dairou, C. Noll, L. Bui, C. Ripoll et al., Mice Deficient in Cystathionine Beta Synthase Display Increased Dyrk1A and SAHH Activities in Brain, Journal of Molecular Neuroscience, vol.174, issue.1, pp.1-6, 2013.
DOI : 10.2353/ajpath.2009.081036

S. Abekhoukh, C. Planque, C. Ripoll, P. Urbaniak, J. Paul et al., Dyrk1A, a Serine/Threonine Kinase, is Involved in ERK and Akt Activation in the Brain of Hyperhomocysteinemic Mice, Molecular Neurobiology, vol.178, issue.1, pp.105-116, 2013.
DOI : 10.1016/j.ajpath.2010.12.052

N. Janel, M. Sarazin, F. Corlier, H. Corne, L. De-souza et al., Plasma DYRK1A as a novel risk factor for Alzheimer???s disease, Translational Psychiatry, vol.37, issue.8, p.425, 2014.
DOI : 10.1155/2006/276239

URL : http://doi.org/10.1038/tp.2014.61

A. Tlili, A. Hoischen, C. Ripoll, E. Benabou, A. Badel et al., BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients, Molecular Neurobiology, vol.12, issue.2, pp.297-303, 2012.
DOI : 10.1007/s00213-004-2137-7

J. Platenik, Z. Fisar, R. Buchal, R. Jirak, E. Kitzlerova et al., GSK3??, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.50, pp.83-93, 2014.
DOI : 10.1016/j.pnpbp.2013.12.001

D. Wald, A. Kasturiratne, and M. Simmonds, Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participants, Alzheimer's & Dementia, vol.7, issue.4, pp.412-417, 2011.
DOI : 10.1016/j.jalz.2010.08.234

R. Sperling, P. Aisen, L. Beckett, D. Bennett, S. Craft et al., Toward defining the preclinical stages of Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.280-292, 2011.
DOI : 10.1016/j.jalz.2011.03.003

T. Grimmer, C. Wutz, A. Drzezga, S. Forster, H. Forstl et al., The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment, Curr Alzheimer Res, vol.10, pp.82-85, 2013.

M. Albert, S. Dekosky, D. Dickson, B. Dubois, H. Feldman et al., The diagnosis of mild cognitive impairment due to Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer???s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.270-279, 2011.
DOI : 10.1016/j.jalz.2011.03.008

G. Mckhann, D. Knopman, H. Chertkow, B. Hyman, C. Jack et al., The diagnosis of dementia due to Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer???s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.263-269, 2011.
DOI : 10.1016/j.jalz.2011.03.005

A. Lazar, C. Bich, M. Panchal, N. Desbenoit, V. Petit et al., Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients, Acta Neuropathologica, vol.29, issue.3, pp.133-144, 2013.
DOI : 10.1016/j.nbd.2007.10.005

URL : https://hal.archives-ouvertes.fr/hal-00772814

F. Guedj, P. Pereira, S. Najas, M. Barallobre, C. Chabert et al., DYRK1A: A master regulatory protein controlling brain growth, Neurobiology of Disease, vol.46, issue.1, pp.190-203, 2012.
DOI : 10.1016/j.nbd.2012.01.007

V. Fotaki, M. Dierssen, S. Alcantara, S. Martinez, E. Marti et al., Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice, Molecular and Cellular Biology, vol.22, issue.18, pp.6636-6647, 2002.
DOI : 10.1128/MCB.22.18.6636-6647.2002

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC135639

L. Bui, L. Tabouy, F. Busi, J. Dupret, J. N. Planque et al., A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase, Analytical Biochemistry, vol.449, pp.172-178, 2014.
DOI : 10.1016/j.ab.2013.12.024

L. Reik, S. Maines, D. Ryan, W. Levin, S. Bandiera et al., A simple, non-chromatographic purification procedure for monoclonal antibodies Isolation of monoclonal antibodies against cytochrome P450 isozymes, Journal of Immunological Methods, vol.100, issue.1-2, pp.123-130, 1987.
DOI : 10.1016/0022-1759(87)90180-3

G. Ellman, K. Courtney, V. Andres, . Jr, and R. Feather-stone, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochemical Pharmacology, vol.7, issue.2, pp.88-95, 1961.
DOI : 10.1016/0006-2952(61)90145-9

J. Grassi, Y. Frobert, P. Pradelles, F. Chercuitte, D. Gruaz et al., Production of monoclonal antibodies against interleukin-1?? and -1??, Journal of Immunological Methods, vol.123, issue.2, pp.193-210, 1989.
DOI : 10.1016/0022-1759(89)90223-8

H. Volland, B. Vulliez-le-normand, S. Mamas, J. Grassi, C. Creminon et al., Enzyme immunometric assay for leukotriene C4, Journal of Immunological Methods, vol.175, issue.1, pp.97-105, 1994.
DOI : 10.1016/0022-1759(94)90335-2

V. Ducros, K. Demuth, M. Sauvant, M. Quillard, E. Causse et al., Methods for homocysteine analysis and biological relevance of the results, Journal of Chromatography B, vol.781, issue.1-2, pp.207-226, 2002.
DOI : 10.1016/S1570-0232(02)00497-X

E. Neto, F. Biessmann, H. Aurlien, H. Nordby, and T. Eichele, Regularized linear discriminant analysis of EEG features in dementia patients 30 Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment, Front Aging Neurosci Annu Rev Nutr, vol.8, issue.36, pp.273-211, 2016.

K. Ori-mckenney, R. Mckenney, H. Huang, T. Li, S. Meltzer et al., Phosphorylation of ??-Tubulin by the Down Syndrome Kinase, Minibrain/DYRK1a, Regulates Microtubule Dynamics and Dendrite Morphogenesis, Neuron, vol.90, issue.3, pp.551-563, 2016.
DOI : 10.1016/j.neuron.2016.03.027

M. Ruiz-mejias, M. Martinez-de-lagran, M. Mattia, P. Castano-prat, L. Perez-mendez et al., , a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex, The Journal of Neuroscience, vol.36, issue.13, pp.3648-3659, 2016.
DOI : 10.1523/JNEUROSCI.2517-15.2016

Y. Lee, J. Ha, H. Kim, Y. Kim, E. Chang et al., Negative Feedback Inhibition of NFATc1 by DYRK1A Regulates Bone Homeostasis, Journal of Biological Chemistry, vol.1, issue.48, pp.33343-33351, 2009.
DOI : 10.1016/S1534-5807(02)00369-6

N. Jin, X. Yin, J. Gu, X. Zhang, J. Shi et al., Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I, Journal of Biological Chemistry, vol.14, issue.24, pp.15219-15237, 2015.
DOI : 10.1212/WNL.41.4.479

R. Duman, G. Aghajanian, G. Sanacora, and J. Krystal, Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants, Nature Medicine, vol.15, issue.3, pp.238-249, 2016.
DOI : 10.1146/annurev-clinpsy-050212-185606

A. Autry and L. Monteggia, Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders, Pharmacological Reviews, vol.64, issue.2, pp.238-258, 2012.
DOI : 10.1124/pr.111.005108

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310485

A. Carrard, A. Salzmann, N. Perroud, J. Gafner, A. Malafosse et al., Genetic association of the Phosphoinositide-3 kinase in schizophrenia and bipolar disorder and interaction with a BDNF gene polymorphism, Brain and Behavior, vol.8, issue.Suppl 1, pp.119-124, 2011.
DOI : 10.1093/hmg/8.9.1729

T. Niitsu, Y. Shirayama, D. Matsuzawa, T. Hasegawa, N. Kanahara et al., Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.35, issue.8, pp.1836-1840, 2011.
DOI : 10.1016/j.pnpbp.2011.09.004

H. Koenigsberg, P. Yuan, G. Diaz, S. Guerreri, C. Dorantes et al., Platelet protein kinase C and brain-derived neurotrophic factor levels in borderline personality disorder patients, Psychiatry Research, vol.199, issue.2, pp.92-97, 2012.
DOI : 10.1016/j.psychres.2012.04.026

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128317

H. Phillips, J. Hains, M. Armanini, G. Laramee, S. Johnson et al., BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease, Neuron, vol.7, issue.5, pp.695-702, 1991.
DOI : 10.1016/0896-6273(91)90273-3

I. Ferrer, C. Marin, M. Rey, T. Ribalta, E. Goutan et al., BDNF and Full-length and Truncated TrkB Expression in Alzheimer Disease. Implications in Therapeutic Strategies, Journal of Neuropathology and Experimental Neurology, vol.58, issue.7, pp.729-739, 1999.
DOI : 10.1097/00005072-199907000-00007

Y. Lu, K. Christian, and B. Lu, BDNF: A key regulator for protein synthesis-dependent LTP and long-term memory?, Neurobiology of Learning and Memory, vol.89, issue.3, pp.312-323, 2008.
DOI : 10.1016/j.nlm.2007.08.018

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387254

B. Diniz and A. Teixeira, Brain-Derived Neurotrophic Factor and Alzheimer???s Disease: Physiopathology and Beyond, NeuroMolecular Medicine, vol.129, issue.4, pp.217-222, 2011.
DOI : 10.1309/W01Y0B808EMEH12L

P. 44-komulainen, M. Pedersen, T. Hanninen, H. Bruunsgaard, T. Lakka et al., BDNF is a novel marker of cognitive function in ageing women: The DR???s EXTRA Study, Neurobiology of Learning and Memory, vol.90, issue.4, pp.596-603, 2008.
DOI : 10.1016/j.nlm.2008.07.014

O. Forlenza, B. Diniz, A. Teixeira, E. Ojopi, L. Talib et al., Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment, The World Journal of Biological Psychiatry, vol.69, issue.5, pp.774-780, 2010.
DOI : 10.4088/JCP.v69n0710

L. Rabaneda, N. Geribaldi-doldan, M. Murillo-carretero, M. Carrasco, J. Martinez-salas et al., Altered regulation of the Spry2/Dyrk1A/PP2A triad by homocysteine impairs neural progenitor cell proliferation, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1863, issue.12, pp.3015-3026, 2016.
DOI : 10.1016/j.bbamcr.2016.09.018

S. Seshadri, A. Beiser, J. Selhub, P. Jacques, I. Rosenberg et al., Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease, New England Journal of Medicine, vol.346, issue.7, pp.476-483, 2002.
DOI : 10.1056/NEJMoa011613

D. Zylberstein, L. Lissner, C. Bjorkelund, K. Mehlig, D. Thelle et al., Midlife homocysteine and late-life dementia in women. A prospective population study, Neurobiology of Aging, vol.32, issue.3, pp.380-386, 2011.
DOI : 10.1016/j.neurobiolaging.2009.02.024

J. Hamelet, J. Couty, A. Crain, C. Noll, C. Postic et al., Calpain activation is required for homocysteine-mediated hepatic degradation of inhibitor Ikappa B alpha, Molecular Genetics and Metabolism, vol.97, issue.2, pp.114-120, 2009.
DOI : 10.1016/j.ymgme.2009.02.005

Y. Jang, J. Kim, J. Ko, and Y. Kwon, Homocysteine induces PUMA-mediated mitochondrial apoptosis in SH-SY5Y cells, Amino Acids, vol.276, issue.11, pp.2559-2569, 2016.
DOI : 10.1074/jbc.M100747200

Y. Zhang, J. Liao, S. Zeng, and H. Lu, p53 downregulates Down syndrome-associated DYRK1A through miR-1246, EMBO reports, vol.21, issue.8, pp.811-817, 2011.
DOI : 10.1093/emboj/cdf540

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147276

M. Zheng, L. Han, B. Wang, L. Wang, P. Liu et al., REST regulates DYRK1A transcription in a negative feedback loop, J Biol Chem, vol.286, pp.10755-10763, 2011.